TAS::75 0849::TAS - PATIENT REPORTED OUTCOMES VERSION OF THE COMMON TERMINOLOGY
TAS::75 0849::TAS - PATIENT REPORTED OUTCOMES VERSION OF THE COMMON TERMINOLOGY
批准号:
8165963
负责人:
ETHAN M. BASCH
金额:
$153.78万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-09-30 至 2015-09-29
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The standard lexicon for reporting adverse events in National Cancer Institute (NCI) sponsored clinical trials is the Common Terminology Criteria for Adverse Events (CTCAE), which consists of 790 individual items. Historically, adverse events have been reported by clinicians. However, multiple studies have found that clinicians tend to underreport symptom severity and onset compared with patient self-reports. In 2008, the NCI contracted a multi-institution consortium to develop a patient-reported outcome (PRO) counterpart instrument to complement to the CTCAE. This system, called PRO-CTCAE provides a web-based platform to collect patient reports of symptoms they are experiencing during treatment for the purpose of enhancing adverse event (AE) reporting. The overall goal of the PRO-CTCAE initiative is to employ rigorous scientific methods to create a system for patient self-reporting of adverse symptoms in cancer trials that is widely accepted, generates useful data for investigators, regulators, clinicians and patients; and is compatible with existing systems for reporting adverse events. 81 symptoms were identified in the CTCAE to be amenable to patient reporting; the measured attributes for each symptom include frequency, severity, and activity interference. Questions and response options were standardized, along with plain language terms for each symptom. A web-based platform was developed and tested for administering the PRO-CTCAE items. The prototype has undergone undergoing testing to assess usability, logistical feasibility, and validity in a variety of cancer care settings. The PRO-CTCAE system has the potential to enhance adverse event reporting by integrating patient experiences and can foster consistency of data collection methods across studies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Analyzing and Interpreting PRO-CTCAE with CTCAE and Other Clinical Data to Characterize Drug Tolerability
-
批准号:10884103
-
项目类别:
-
资助金额:$26.92万
-
财政年份:2023
-
负责人:ETHAN M. BASCH
-
依托单位:
Analyzing and Interpreting PRO-CTCAE with CTCAE and Other Clinical Data to Characterize Drug Tolerability
-
批准号:9789216
-
项目类别:
-
资助金额:$53.77万
-
财政年份:2018
-
负责人:ETHAN M. BASCH
-
依托单位:
Analyzing and Interpreting PRO-CTCAE with CTCAE and Other Clinical Data to Characterize Drug Tolerability
-
批准号:10005036
-
项目类别:
-
资助金额:$53.09万
-
财政年份:2018
-
负责人:ETHAN M. BASCH
-
依托单位:
Analyzing and Interpreting PRO-CTCAE with CTCAE and Other Clinical Data to Characterize Drug Tolerability
-
批准号:10475645
-
项目类别:
-
资助金额:$55.43万
-
财政年份:2018
-
负责人:ETHAN M. BASCH
-
依托单位:
TAS::75 0849::TAS - PATIENT REPORTED OUTCOMES VERSION OF THE COMMON TERMINOLOGY
-
批准号:8338732
-
项目类别:
-
资助金额:$176.98万
-
财政年份:2010
-
负责人:ETHAN M. BASCH
-
依托单位:
Tracking Symptoms during Chemotherapy via Online Patient Self-reporting
-
批准号:7922782
-
项目类别:
-
资助金额:$10.0万
-
财政年份:2009
-
负责人:ETHAN M. BASCH
-
依托单位:
Tracking Symptoms during Chemotherapy via Online Patient Self-reporting
-
批准号:7778917
-
项目类别:
-
资助金额:$13.4万
-
财政年份:2008
-
负责人:ETHAN M. BASCH
-
依托单位:
Cancer Care Quality Research Training Program
-
批准号:8904622
-
项目类别:
-
资助金额:$42.98万
-
财政年份:2008
-
负责人:ETHAN M. BASCH
-
依托单位:
R&D-OTHER R & D-A RES/EXPL DEV
-
批准号:8125388
-
项目类别:
-
资助金额:$86.22万
-
财政年份:2008
-
负责人:ETHAN M. BASCH
-
依托单位:
Tracking Symptoms during Chemotherapy via Online Patient Self-reporting
-
批准号:7385463
-
项目类别:
-
资助金额:$13.4万
-
财政年份:2008
-
负责人:ETHAN M. BASCH
-
依托单位:
Cancer Care Quality Research Training Program
-
批准号:8473574
-
项目类别:
-
资助金额:$45.7万
-
财政年份:2008
-
负责人:ETHAN M. BASCH
-
依托单位:
Cancer Care Quality Research Training Program
-
批准号:8710025
-
项目类别:
-
资助金额:$45.45万
-
财政年份:2008
-
负责人:ETHAN M. BASCH
-
依托单位:
Cancer Care Quality Research Training Program
-
批准号:9129603
-
项目类别:
-
资助金额:$40.5万
-
财政年份:2008
-
负责人:ETHAN M. BASCH
-
依托单位:
Tracking Symptoms during Chemotherapy via Online Patient Self-reporting
-
批准号:8234807
-
项目类别:
-
资助金额:$13.33万
-
财政年份:2008
-
负责人:ETHAN M. BASCH
-
依托单位:
Tracking Symptoms during Chemotherapy via Online Patient Self-reporting
-
批准号:8042678
-
项目类别:
-
资助金额:$13.4万
-
财政年份:2008
-
负责人:ETHAN M. BASCH
-
依托单位:
Tracking Symptoms during Chemotherapy via Online Patient Self-reporting
-
批准号:7596485
-
项目类别:
-
资助金额:$13.4万
-
财政年份:2008
-
负责人:ETHAN M. BASCH
-
依托单位:
R&D-OTHER R & D-A RES/EXPL DEV
-
批准号:7952669
-
项目类别:
-
资助金额:$104.98万
-
财政年份:2008
-
负责人:ETHAN M. BASCH
-
依托单位:
Cancer Care Quality Training Program
-
批准号:10221611
-
项目类别:
-
资助金额:$33.66万
-
财政年份:2005
-
负责人:ETHAN M. BASCH
-
依托单位:
Cancer Care Quality Research Training Program
-
批准号:9348589
-
项目类别:
-
资助金额:$40.14万
-
财政年份:2005
-
负责人:ETHAN M. BASCH
-
依托单位:
Cancer Care Quality Training Program
-
批准号:10459369
-
项目类别:
-
资助金额:$30.7万
-
财政年份:2005
-
负责人:ETHAN M. BASCH
-
依托单位:
国内基金
海外基金
登录
查看更多内容
ProBDNF/p75NTR轴在肠缺血再灌注损伤中的神经-免疫调控作用
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:沈玮云
-
依托单位:
IP3R/GRP75/VDAC1介导内质网应激—线粒体氧化应激调控慢传输型便秘ICC凋亡的机制及生血通便颗粒的干预作用
-
批准号:2026JJ82078
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:罗雯鹏
-
依托单位:
转录因子ZmbZIP75调控玉米籽粒成熟脱水的分子机制与育种应用研究
-
批准号:2026JJ60400
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:龙田丹
-
依托单位:
LRRC75A通过结合THRAP3调控ANXA1-ERK信号通路在结直肠癌增殖中的作用及机制研究
-
批准号:2026JJ50308
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:梁纶熙
-
依托单位:
铁皮石斛菌根真菌在干旱逆境下调控CYP75B1促进黄酮合成的机制
-
批准号:2026JJ50408
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:许璐
-
依托单位:
Listerin表达下调通过抑制HSP75介导线粒体稳态失衡在溃疡性结肠炎抗TNF-α治疗无应答中的作用机制研究
-
批准号:2026JJ80700
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:向仍运
-
依托单位:
FLOT1-GCEVs通过GRP75诱导肝细胞线粒体功能障碍和PMN的形成促进胃癌肝转移的作用及机制研究
-
批准号:2026JJ60297
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:王然
-
依托单位:
贯叶金丝桃素调控proBDNF/p75NTR- γδ T轴在抑郁促进银屑病进展中的机制研究
-
批准号:JCZRQN202500195
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
CmWRKY75转录因子调控枸橼C-05溃疡病抗性的分子机制
-
批准号:2025JJ60177
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:曹运琳
-
依托单位:
P75NTR调控巨噬细胞糖酵解在脓毒症肠损伤中的作用和机制研究
-
批准号:2025JJ50633
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:沈玮云
-
依托单位: